Status:
COMPLETED
Effect of Cross Frequency tACS on Cognitive Control
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Cognitive Control
Executive Function
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex
Detailed Description
Previous evidence suggests that there are specific frequency bands associated with different aspects of cognitive control. In specific delta (2-4Hz) and beta (15-30Hz) are associated with increased le...
Eligibility Criteria
Inclusion
- Between the ages of 18 and 35 years
- Able to provide informed consent
- Willing to comply with all study procedures and be available for the duration of the study Speak and understand English
Exclusion
- Attention Deficit Hyperactivity Disorder (currently under treatment)
- Neurological disorders and conditions, including, but not limited to:
- History of epilepsy
- Seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) Dementia
- History of stroke
- Parkinson's disease
- Multiple sclerosis
- Cerebral aneurysm
- Brain tumors
- Medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, malignancy)
- Prior brain surgery
- Any brain devices/implants, including cochlear implants and aneurysm clips
- History or current traumatic brain injury
- (For females) Pregnancy or breast feeding
- Personal or family history of mental/psychiatric disorder (e.g., anxiety, major depressive disorder, schizophrenia, etc.)
- Positive urine test for the following: Marijuana (THC), Cocaine (COC), Phencyclidine (PCP), Amphetamine (AMP), Ecstasy (MDMA), Methamphetamine (Mamp), Opiates (OPI), Oxycodone (OXY), Methadone (MTD), Barbiturates (BAR), Benzodiazepines (BZO), Buprenorphine (BUP), Tricyclic Antidepressants (TCA), Propoxyphene (PPX)
- Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
Key Trial Info
Start Date :
October 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2019
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03800030
Start Date
October 7 2018
End Date
July 25 2019
Last Update
May 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, United States, 27599